Position in PGEN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$525,364
-$2,292,826 QoQ
Shares Held
135,753
-84.2% QoQ
Ownership
0.038%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2022
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PGEN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Schonfeld Strategic Advisors LLC holds $296,187,490 across 126 Biotechnology names. PGEN ranks #58 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | FOLD |
AMICUS THERAPEUTICS, INC.
|
1,757,899 | $25,419,219 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
71,767 | $23,745,547 | |
| 3 | PTCT |
Ptc Therapeutics, Inc.
|
318,405 | $21,692,932 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
324,722 | $18,882,584 | |
| 5 | INBX |
Inhibrx Biosciences, Inc.
|
254,827 | $17,132,019 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
62,142 | $11,747,945 | |
| 7 | RARE |
Ultragenyx Pharmaceutical Inc.
|
494,737 | $10,364,740 | |
| 8 | INSM |
INSMED Inc
|
56,056 | $9,166,277 |
All Filings in PGEN
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $525,364 | 135,753 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $2,818,190 | 856,593 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $2,042,617 | 1,438,463 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $4,163,431 | 2,794,249 | Shares | Sole | 2025-05-15 | |
| 2022-09-30 | $156,456 | 73,800 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $181,570 | 135,500 | Shares | Sole | 2022-08-15 | |
| 2022-03-31 | $377,479 | 178,900 | Shares | Sole | 2022-05-16 | |
| No filing history on record for this holder in this stock. | ||||||